A practical approach to diagnosis and treatment of symptomatic thromboembolic events in children with acute lymphoblastic leukemia: Recommendations of the "coagulation defects" AIEOP Working Group

Recent Patents on Cardiovascular Drug Discovery

Volumn 2, Issue 1, 2007, Pages 53-62

  Giordano, Paola ^a   Del Vecchio, Giovanni Carlo ^a   Saracco, Paola ^b   Zecca, Marco ^c   Molinari, Angelo Claudio ^d   De Mattia, Domenico ^a   Del Principe, Domenico ^e   Jankovic, Moncilo ^e   Nobili, Bruno ^e   Nardi, Margherita ^e   Ramenghi, Ugo ^e   Russo, Giovanna ^e   Santoro, Nicola ^e  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d G GASLINI INSTITUTE   (Italy)

^e NONE

Author keywords

Acute lymphoblastic leukaemia; Diagnosis; Pediatric; Thromboembolism; Treatment

Indexed keywords

ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; CORTICOSTEROID; DALTEPARIN; DEXTRAN; DIPYRIDAMOLE; ENOXAPARIN; FIBRINOGEN; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTAMINE SULFATE; RECOMBINANT PLASMINOGEN ACTIVATOR; REVIPARIN; SALICYLIC ACID; TICLOPIDINE; TINZAPARIN; WARFARIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLEEDING; CANCER SURVIVAL; CANCER SURVIVOR; CENTRAL VENOUS CATHETERIZATION; CHILD; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG HALF LIFE; DRUG WITHDRAWAL; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; PATENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; THROMBOSIS;

CATHETERIZATION, CENTRAL VENOUS; CHILD; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; THROMBOEMBOLISM; THROMBOLYTIC THERAPY;

EID: 34249274972     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489007779606077     Document Type: Article

References (70)

1. Coebergh JW, Pastore G, Gatta G, Corazziari I, Kamps W. Variation in survival of European children with acute lymphoblastic leukaemia, diagnosed in 1978-1992: the EUROCARE study. Eur J Cancer 2001; 37:687-694.
2. Gatta G, Capocaccia R, Stiller C, Kaatsch P, Berrino F, Terenziani M. Childhood cancer survival trends in Europe: a EUROCARE Working Group study. J Clin Oncol 2005; 23: 3742-3751.
3. Willman C.L., Helman P., Veroff R., Mosquera-Caro M., Davidson G.S., Martin S.B., Atlas S.R., Andries E., Kang H., Shuster J.J., Wang X., Harvey R.C., Haaland D.M., Potter J.W.: US20060063156A1 (2006)
4. Willman C.L., Helman P., Veroff R., Mosquera-Caro M., Davidson G.S., Martin S.B., Atlas S.R., Andries E., Kang H., Shuster J.J., Haaland D.M., Potter J.W., Wang X., Harvey R.C.: WO04053074A2 (2004).
5. Journeycake JM, Manco-Johnson MJ. Thrombosis during infancy and childhood: what we know and what we do not know. Hematol Oncol Clin North Am 2004; 18:1315-13.
6. Bajzar L, Chan AK, Massicotte MP, Mitchell LG. Thrombosis in children with malignancy. Curr Opin Pediatr 2006; 18:1-9.
7. Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thromb Res 2003; 111:125-131.
8. Nowak-Gottl U, Wermes C, Junker R, et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999; 93:1595-1599.
9. Mauz-Korholz C, Junket R, Gobel U, Nowak-Gottl U. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols). Thromb Haemost 2000; 83:840-843.
10. Glaser DW, Medeiros D, Rollins N, Buchanan GR. Catheter-related thrombosis in children with cancer. J Pediatr 2001; 138:255-259.
11. Mitchell LG, Andrew M, Hanna K, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) Study. Cancer 2003; 97:508-516.
12. Giordano P, Santoro N, Del Vecchio GC, Rizzari C, Masera G, De Mattia D. T-immunophenotype is associated with an increased prevalence of thrombosis in children with acute lymphoblastic leukemia. A retrospective study. Haematologica 2003; 88:1079-1080.
13. Caruso V, Iacoviello L, Di Castelnuovo, et al. Thrombotic complications in childhood acute lymphoblastic leukemia. A meta-analysis of 17 prospective studies comprising 1,752 pediatric patients. Blood 2006; 108: 2216-2222.
14. Manco-Johnson MJ. Postthrombotic syndrome in children. Acta Haematol 2006; 115: 207-213.
15. Goldenberg NA, Manco-Johnson MJ. Pediatric hemostasis and use of plasma components. Best Pract Res Clin Haematol 2006; 19:143-155.
16. Santoro N, Giordano P, Del Vecchio GC, et al. Ischemic stroke in children treated for acute lymphoblastic leukemia: a retrospective study. J Pediatr Hematol Oncol 2005; 27:153-157.
17. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001; 102:215-224.
18. Sutherland DE, Weitz IC, Liebman HA. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol 2003; 72:43-52.
19. Giordano P, Del Vecchio GC, Saracco P, et al. Hemostatic alterations in pediatric leukemias. Pathophysiol Haemost Thromb 2003; 33:97-98.
20. Massicotte MP, Dix D, Monagle P, Adams M, Andrew M. Central venous catheter related thrombosis in children: Analysis of the canadian registry of venous thromboembolic complications. J Pediatr 1998; 133:770-776.
21. Male C, Chait P, Andrew M, Hanna K, Julian J, Mitchell L. Central venous line-related thrombosis in children: association with central venous line location and insertion technique. Blood 2003; 101: 4273-4278.
22. Molinari AC, Castagnola E, Mazzola C, Piacentino M, Fratino G. Thromboembolic complications related to indwelling central venous catheters in children with oncological/haematological diseases: a retrospective study of 362 catheters. Support Care Cancer 2001; 9: 539-544.
23. Bick RL. Cancer-associated thrombosis. N Engl J Med 2003; 349:109-111.
24. Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res 2003; 111:199-212.
25. Nowak-Gottl U, Heinecke A, von Kries R, Numberger W, Munchow N, Junker R. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/ prednisone administration. Thromb Res 2001; 103:165-172.
26. Nowak-Gottl U, Ahlke E, Fleischhack G, et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood 2003; 101:2529-2533.
27. Manco-Johnson MJ, Nuss R. Thrombophilia in the infant and child. Adv Pediatr 2001; 48:363-384.
28. Kirkham FJ. Stroke in childhood. Arch Dis Child 1999; 81:85-89.
29. deVeber G, Andrew M, Adams C, et al. Cerebral sinovenous thrombosis in children. N Engl J Med 2001; 345:417-423.
30. Lynch JK, Hirtz DG, deVeber G, Nelson KB. Report of the national institute of neurological disorders and stroke workshop on perinatal and childhood stroke. Pediatrics 2002; 109:116-123.
31. Revel-Vilk S, Massicotte P. Thromboembolic diseases of childhood. Blood Rev 2003; 17:1-6.
32. Male C, Chait P, Ginsberg JS, et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic antithrombin replacement in kids with all treated with asparaginase. Thromb Haemost 2002; 87:593-598.
33. Kearon C. Diagnosis of pulmonary embolism. CMAJ 2003; 168:183-194.
34. Goldhaber SZ. Echocardiography in the management of pulmonary embolism. Ann Intern Med 2002; 136:691-700.
35. Fedullo PF, Tapson VF. Clinical practice. The evaluation of suspected pulmonary embolism. N Engl J Med 2003; 349:1247-1256.
36. Wintermark M, Bogousslavsky J. Imaging of acute ischemic brain injury: the return of computed tomography. Curr Opin Neurol 2003; 16:59-63.
37. Ganesan V, Savvy L, Chong WK, Kirkham FJ. Conventional cerebral angiography in children with ischemic stroke. Pediatr Neurol 1999; 20:38-42.
38. Gomes MP, Deitcher SR. Diagnosis of venous thromboembolic disease in cancer patients. Oncology 2003; 17:126-135, 139.
39. ten Wolde M, Kraaijenhagen RA, Prins MH, Buller HR. The clinical usefulness of D-dimer testing in cancer patients with suspected deep venous thrombosis. Arch Intern Med 2002; 162:1880-1884.
40. Lee AY, Julian JA, Levine MN, et al. Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis. Ann Intern Med 1999; 131:417-423.
41. Schutgens RE, Esseboom EU, Haas FJ, Nieuwenhuis HK, Biesma DH. Usefulness of a semiquantitative D-dimer test for the exclusion of deep venous thrombosis in outpatients. Am J Med 2002; 112:617-621.
42. Young G. Diagnosis and treatment of thrombosis in children: general principles. Pediatr Blood Cancer 2006; 46:540-546.
43. De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica 2002; 87:1095-1108.
44. Andrew M, Monagle PT, Brooker LA. Thromboembolic complications during infancy and childhood. Hamilton, Ont; Lewiston, N.Y., B.C. Decker, 2000.
45. Manco-Johnson MJ. How I treat venous thrombosis in children. Blood 2006; 107:21-29.
46. Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD. Antithrombotic therapy in children: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126:645S-687S.
47. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126:188-203.
48. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349:146-153.
49. Lee AY. Treatment and secondary prophylaxis of VTE in the cancer patient: current status. Pathophysiol Haemost Thromb 2003; 1:42-43.
50. Molinari AC, Haupt R, Saracco P, Di Marco M, Castagnola E, Fratino G. Urokinase for restoring patency of malfunctioning or blocked central venous catheters in children with hemato-oncological diseases. Support Care Cancer 2004; 12:840-843.
51. Wiernikowski JT, Athale UH. Thromboembolic complications in children with cancer. Thromb Res 2006; 118:137-52.
52. Massicotte P, Julian JA, Gent M, et al. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res 2003; 109:85-92.
53. Castagnola E, Molinari AC, Fratino G, Viscoli C. Conditions associated with infections of indwelling central venous catheters in cancer patients: a summary. Br J Haematol 2003; 121:233-239.
54. Nohe N, Flemmer A, Rumler R, Praun M, Auberger K. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. Eur J Pediatr 1999; 158:134-139.
55. White RH, Ginsberg JS. Low-molecular-weight heparins: are they all the same? Br J Haematol 2003; 121:12-20.
56. Massicotte MP. Low-molecular-weight heparin therapy in children. J Pediatr Hematol Oncol 2001; 23:189-194.
57. Haire WD, Atkinson JB, Stephens LC, Kotulak GD. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial. Thromb Haemost 1994; 72:543-547.
58. Choi M, Massicotte MP, Marzinotto V, Chan AK, Holmes JL, Andrew M. The use of alteplase to restore patency of central venous lines in pediatric patients: a cohort study. J Pediatr 2001; 139:152-156.
59. Wang M, Hays T, Balasa V, et al. Low-dose tissue plasminogen activator thrombolysis in children. J Pediatr Hematol Oncol 2003; 25:379-386.
60. Chan AK, deVeber G, Monagle P, Brooker LA, Massicotte PM. Venous thrombosis in children. J Thromb Haemost 2003; 1:1443-1455.
61. Manco-Johnson MJ, Nuss R, Hays T, Krupski W, Drose J, Manco-Johnson ML. Combined thrombolytic and anticoagulant therapy for venous thrombosis in children. J Pediatr 2000; 136:446-453.
62. Chalmers EA, Gibson BE. Thrombolytic therapy in the management of paediatric thromboembolic disease. Br J Haematol 1999; 104:14-21.
63. DeVeber G, Chan A, Monagle P, et al. Anticoagulation therapy in patients with sinovenous thrombosis. Arch Neurol 1998; 55:1533-1537.
64. Johnson MC, Parkerson N, Ward S, deAlarcon P. Pediatric sinovenous thrombosis. J Ped Hematol Oncol 2003; 25:312-315.
65. Streif W, Monagle P, South M, Leaker M, Andrew M. Spontaneous arterial thrombosis in children. J Pediatr 1999; 134:110-112.
66. Elhasid R, Lanir N, Sharon R, et al. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 2001; 12:367-70.
67. Misselwitz F., Kubitza D., Park S.-M., Wehling K.: WO06079474 (2006).
68. Eisert W., Serebruany V.L.: WO05113006 (2005).
69. Boyer J., Olins G.M., Yerxa B.R., Douglass III J.G.: US20067018985 ( 2006).
70. De Mattia D, Del Principe D, Del Vecchio GC, et al. Acute childhood idiopathic thrombocytopenic purpura: AIEOP consensus guidelines for diagnosis and treatment. Haematologica 2000; 85: 420-24.